ICU vs. CODX, LNSR, MODD, CTCX, XAIR, GBS, RVP, AKLI, MDAI, and DRIO
Should you be buying SeaStar Medical stock or one of its competitors? The main competitors of SeaStar Medical include Co-Diagnostics (CODX), LENSAR (LNSR), Modular Medical (MODD), Carmell (CTCX), Beyond Air (XAIR), GBS (GBS), Retractable Technologies (RVP), Akili (AKLI), Spectral AI (MDAI), and DarioHealth (DRIO). These companies are all part of the "surgical & medical instruments" industry.
SeaStar Medical (NASDAQ:ICU) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
In the previous week, SeaStar Medical had 2 more articles in the media than Co-Diagnostics. MarketBeat recorded 3 mentions for SeaStar Medical and 1 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.00 beat SeaStar Medical's score of -0.03 indicating that Co-Diagnostics is being referred to more favorably in the news media.
Co-Diagnostics has a consensus target price of $2.50, suggesting a potential upside of 98.41%. Given Co-Diagnostics' higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than SeaStar Medical.
Co-Diagnostics received 272 more outperform votes than SeaStar Medical when rated by MarketBeat users. However, 100.00% of users gave SeaStar Medical an outperform vote while only 63.49% of users gave Co-Diagnostics an outperform vote.
1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 4.5% of SeaStar Medical shares are owned by company insiders. Comparatively, 2.4% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
SeaStar Medical has higher earnings, but lower revenue than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.
SeaStar Medical has a beta of -0.96, suggesting that its stock price is 196% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500.
SeaStar Medical has a net margin of 0.00% compared to Co-Diagnostics' net margin of -518.69%. SeaStar Medical's return on equity of 0.00% beat Co-Diagnostics' return on equity.
Summary
SeaStar Medical beats Co-Diagnostics on 8 of the 15 factors compared between the two stocks.
Get SeaStar Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SeaStar Medical Competitors List
Related Companies and Tools
